MedTrace Logo

Fibrosis and Metabolic Markers in Relation to PREVENT Cardiovascular Risk in MASLD

NCT07791589 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 271

Last updated 2026-08-28

No results posted yet for this study

Summary

This retrospective observational study evaluates the relationship between non-invasive liver fibrosis and metabolic markers and estimated cardiovascular risk in adults with metabolic dysfunction-associated steatotic liver disease (MASLD). The primary objective is to assess the association between the Fibrosis-4 index (FIB-4) and 10-year cardiovascular disease risk estimated using the American Heart Association PREVENT equations, with particular attention to the effect of age on this association. Secondary analyses evaluate the Fibrosis-3 index (FIB-3), triglyceride-glucose index (TyG), and liver stiffness measurement (LSM) in relation to PREVENT-estimated risks of cardiovascular disease, atherosclerotic cardiovascular disease, and heart failure.

Conditions

  • Metabolic Dysfunction-Associated Steatotic Liver Disease

Sponsors & Collaborators

  • Özgür Bahadır

    lead OTHER

Eligibility

Min Age
30 Years
Max Age
79 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-06-01
Primary Completion
2026-07-01
Completion
2026-07-01

Countries

  • Turkey (Türkiye)

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07791589 on ClinicalTrials.gov